Press Releases & Media Highlights

Vycellix CEO to Present Strategies for Enhancing Next-Generation NK Cell Cancer Therapy at Innate Killer Summit

TAMPA, FLORIDA & STOCKHOLM, SWEDEN – March 15, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned ...
Read More

Cell & Gene Immunotherapy Biotech, Vycellix, to Establish Headquarters in Tampa

Vycellix is advancing pipeline of modulators and next-generation T cell & NK cell therapies for treatment of cancers Company to present on Cell Therapy Manufacturing Panel ...
Read More

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer

Studies designed to enhance T cell and NK cell potencies through improved genetic modification and increased cytolytic granules SARASOTA and TAMPA, Fla. – Feb. 27, 2017 ...
Read More

Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit

New Products Enhance Genetic Modification of Lymphocytes  and Significantly Amplify Cancer Killing Capacity Sarasota, Fla. – May 2, 2016 – Vycellix, Inc., a privately-held biotechnology company ...
Read More

Comments are closed.